La meg slå fast med en gang at TRVX er ekstremt lavt priset NOK 440.00M
Corporate description / mission:
Targovax ASA is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2016
Remarks on ownership / listings
2010: Targovax founded on the basis of the history from Norsk Hydro by inventors of the RAS-targeted technology and The Radium Hospital Research Foundation
Categorization
Sector: * Biotechnology - Therapeutics and Diagnostics
Subsector: * Other
- Gene therapy
- Immunotherapy
- Peptides
- Vaccines
Primary therapeutic areas: * Neoplasms / cancer / oncology
Business model: * Other
- In-licensing
- Out-licensing
- R&D
Customer segments: * Other
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 1 | |
|---|---|---|
| Phase I: | 5 | |
| Phase II: | 2 |
Description of products:
ONCOS-102
TG01
TG02
Technology used:
ONCOS adenovirus platform:
Targovax’s cancer immunotherapeutic technology has a targeted mechanism of action making tumors visible to the immune system and educating the immune system to recognize and attack patient specific tumor cells. The technology is based on adenoviruses engineered to kill tumor cells primarily via activation of a systemic, patient-targeted anti-tumor immune response. Its lead clinical agent in this area is ONCOS-102.
This immunotherapy technology is designed to enhance the body’s natural immune response by:
•Strengthening response in known immunogenic tumors by enhancing already present T cell responses by providing powerful co-stimulation
•Expanding immunotherapy to less immunogenic tumor types by educating the immune system to recognize and attack tumors in patients with little or no pre-existing functional anti-tumor immune Activity
Why adenovirus? The ability of adenovirus to activate CD8+ T cells makes it an optimal choice for cancer immunotherapy, differentiating it from vaccinia and HSV-based platforms, which are less effective at priming CD8+ T cell responses.
TG mutRAS neoantigen vaccine:
Past efforts at developing TG mutRAS neoantigen vaccine based on peptides have failed because of the length of peptides selected: peptides of a much shorter length were used that activated MHC class I dependent CD8+ cytotoxic T cells but, importantly, had no effect on the critical, MHC class II dependent, CD4+ helper T cells. This approach therefore took no account of the fact that this generation of new CD8+ cytotoxic T cells must go through a MHC class II dependent step.
Targovax has designed its TG neoantigen immunotherapy with peptides that are sufficiently long as to be recognized by MHC class II complexes, and their degradation products can be recognized by MHC class I complexes. Targovax’s targeted immunotherapies are therefore able to activate both CD8+ cytotoxic T cells and CD4+ helper T cells.
Financing details
Market cap. / valuation: NOK 549.32M
Financing details:
Market capitalization as on 23 Sep 18.
